Treating tumors with immune-related therapies is one of the most exciting and promising advancements made in the past decade. Cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market. TIGIT is an im...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
GPR-ICI
Exploration of targeting GPR56 and its cancer cell ligand as...
150K€
Cerrado
CAN-IT-BARRIERS
Disruption of systemic and microenvironmental barriers to i...
3M€
Cerrado
RARITY
RAtional design of canceR ImmunoTherapY one size does not f...
1M€
Cerrado
VITNK
VITNK - deciphering vitamin A and D regulation of human NK c...
207K€
Cerrado
PRE2018-083445
INMUNOTERAPIA DE TUMORES SOLIDOS CON CELULAS T SECRETORAS DE...
93K€
Cerrado
GLIOVACC
Augmenting and broadening T cell responses to glioblastoma...
150K€
Cerrado
Información proyecto TIGITtherapy
Duración del proyecto: 19 meses
Fecha Inicio: 2017-05-11
Fecha Fin: 2018-12-31
Descripción del proyecto
Treating tumors with immune-related therapies is one of the most exciting and promising advancements made in the past decade. Cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market. TIGIT is an important checkpoint inhibitory receptor discovered by our group in 2009. It is constitutively expressed by various immune cells and its expression is further increased on tumor infiltrating lymphocytes (TILs). TIGIT recognizes two main ligands, PVR and Nectin2 that are highly expressed on various tumors. Blockage of TIGIT on TILs either alone or in combination with another checkpoint inhibitory receptor, PD-1, leads to increased T and Natural Killer (NK) cell activity in vitro and inhibited tumor growth in vivo. We developed 9 different anti-TIGIT mAbs during my BacNK ERC advanced grant and previously. In the POC grant TIGITtherapy, which already attracted interest from several bio pharma companies, I propose testing which of the 9 anti-TIGIT mAbs and TIGIT-Ig are able to antagonize TIGIT activity.